For the three months and year ended December 31, 2024, the Company recorded a net loss attributable to common stockholders of ...

"It just ... it ruined his life. Ruined it. Completely ruined his life in 12 seconds," said Tim Kingerski, Ryan's father.

Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. "MyRisk's clear, actionable results provide the foundation for ...

Proposed legislation would clarify that direct primary care doctors are not part of the insurance industry and aren't ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Officials say the collaboration will strengthen emergency response capabilities and ensure residents have continued access to ...

NeuroPace Inc. recently announced that it has entered into a stock purchase agreement with KCK Ltd. The agreement, dated February 13, 2025, outlines the Company’s commitment to repurchase all shares ...

The Department of Justice (DOJ) released its annual False Claims Act (FCA) enforcement statistics on January 15, 2025, announcing that it ...